| Outcome |
Relative effect
(95% CI) |
Absolute effect
(95% CI)1 |
Certainty of the Evidence
(GRADE) |
Clinical improvement
D28 |
RR: 1.00
(0.82 - 1.22) |
0 fewer per 1000
(from 69 fewer to 85 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious
despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious
due to low number of participants/events
|
| 1 trials
Bikdeli B, 2021
598 participants
|
|
Intermediate-Dose prophylactic anticoagulation
385 per 1,000
(315 - 469) |
Standard-Dose prophylactic anticoagulation
385
per 1,000 |
|
Clinical improvement
D60 |
RR: 1.00
(0.82 - 1.22) |
0 fewer per 1000
(from 69 fewer to 85 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious
despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious
due to low number of participants/events
|
| 1 trials
Bikdeli B, 2021
598 participants
|
|
Intermediate-Dose prophylactic anticoagulation
385 per 1,000
(315 - 469) |
Standard-Dose prophylactic anticoagulation
385
per 1,000 |
|
WHO progression score (level 7 or above)
D28 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D60 |
RR: 1.04
(0.91 - 1.18) |
24 more per 1000
(from 54 fewer to 107 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious
despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Bikdeli B, 2021
598 participants
|
|
Intermediate-Dose prophylactic anticoagulation
619 per 1,000
(542 - 702) |
Standard-Dose prophylactic anticoagulation
595
per 1,000 |
|
All-cause mortality
D28 |
RR: 0.99
(0.82 - 1.19) |
3 fewer per 1000
(from 63 fewer to 66 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Serious
Risk of bias downgraded by 1 level:some concern regarding deviation from intended intervention, missing data and selection of reported results Inconsistency: Not serious Indirectness: Not serious Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 2 trials
Perepu U, 2021; Bikdeli B, 2021
774 participants
|
|
Intermediate-Dose prophylactic anticoagulation
345 per 1,000
(286 - 415) |
Standard-Dose prophylactic anticoagulation
349
per 1,000 |
|
All-cause mortality
D60 |
RR: 1.03
(0.85 - 1.25) |
12 more per 1000
(from 62 fewer to 103 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Serious
Risk of bias downgraded by 1 level:some concern regarding missing data and selection of reported results Inconsistency: Not serious Indirectness: Serious
despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Bikdeli B, 2021
598 participants
|
|
Intermediate-Dose prophylactic anticoagulation
424 per 1,000
(350 - 514) |
Standard-Dose prophylactic anticoagulation
411
per 1,000 |
|
Viral negative conversion
D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
Outcome not yet measured or reported
|
|
Serious adverse events
|
RR: 1.01
(0.85 - 1.21) |
5 more per 1000
(from 68 fewer to 96 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious
despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Bikdeli B, 2021
598 participants
|
|
Intermediate-Dose prophylactic anticoagulation
459 per 1,000
(387 - 550) |
Standard-Dose prophylactic anticoagulation
455
per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
